Pharmacokinetic and pharmacodynamic synergism between neuropeptides and lithium in the neurotrophic and neuroprotective action of cerebrolysin

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 2015, Issue 3, 2015, Pages 65-72

  Gromova, O A ^a   Torshin, I Yu ^b   Gogoleva, I V ^a   Pronin, A V ^a   Stelmashuk, E V ^c   Isaev, N K ^c   Genrikhs, E E ^c   Demidov, V I ^a   Volkov, A Yu ^b   Khaspekov, G L ^a   Alexandrova, O P ^c  

^a IVANOVO STATE MEDICAL ACADEMY   (Russian Federation)

^b Russian Satellite Center   (Russian Federation)

^c RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

Author keywords

Histology; Lithium; Model of chronic bilateral occlusion of common carotid arteries; Neurocytology; Neuropeptides

Indexed keywords

CEREBROLYSIN; LITHIUM; NEUROPEPTIDE; NEUROTROPHIC FACTOR; TRACE ELEMENT; AMINO ACID; ENKEPHALIN; GALANIN; GLUTAMIC ACID; LITHIUM DERIVATIVE; NEUROPROTECTIVE AGENT; OREXIN; OREXINS; SIGNAL PEPTIDE;

ARTICLE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; DRUG POTENTIATION; HUMAN; MORPHOLOGICAL ADAPTATION; NERVE CELL CULTURE; NEUROPROTECTION; PHARMACODYNAMICS; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; INBRED RAT STRAIN; MALE; METABOLISM; PATHOLOGY; RAT; STROKE;

AMINO ACIDS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENKEPHALINS; GALANIN; GLUTAMIC ACID; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LITHIUM COMPOUNDS; MALE; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; OREXINS; RATS; RATS, INBRED STRAINS; STROKE;

EID: 84962040781     PISSN: 19977298     EISSN: 23094729     Source Type: Journal    
DOI: 10.17116/jnevro20151153165-72     Document Type: Article

References (18)

1. Chen C., Wei S., Tsaia S., Chen X., Cho D. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebocontrolled, randomized study. Br J Neurosurg 2013; 27: 6: 803-807.
2. Vazquez-Roque R., Ubhi K., Masliah E., Flores G. Chronic cerebrolysin administration attenuates neuronal abnormalities in the basolateral amygdala induced by neonatal ventral hippocampus lesion in the rat. Synapse 2014; 68: 1: 31-8.
3. Georgy G., Nassar N., Mansour H., Abdallah D. Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats. PLoS One 2013; 8: 6: 64847.
4. Allagui M., Nciri R., Rouhaud M., Murat J., El Feki A., Croute F., Vincent C. Long-term exposure to low lithium concentrations stimulates proliferation, modifies stress protein expression pattern and enhances resistance to oxidative stress. Neurochem Res 2009; 34: 3: 453-462.
5. Sharifzadeh M., Aghsami M., Gholizadeh S., Tabrizian K., Soodi M., Khalaj S., Ranjbar A., Hosseini-Sharifabad A., Roghani A., Karimfar M. Protective effects of chronic lithium treatment against spatial memory retention deficits induced by the protein kinase AII inhibitor H-89 in rats. Pharmacology 2007; 80: 2-3: 158-165.
6. Lyoo I., Dager S., Kim J., Yoon S., Friedman S., Dunner D., Renshaw P. Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacol 2010; 35: 8: 1743-1750.
7. Gold A., Herrmann N., Lanctot K. Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-ischemic stroke sequelae. Curr Drug Targets 2011; 12: 2: 243-255.
8. Combs D.J., D’Alecy L. Functional Assessment After Cerebral Ischemia. Stroke 1987; 18: 2: 503-511.
9. Nordhoff E., Schurenberg M., Thiele G., Lubbert C., Kloeppel K.-D., Theiss D., Lechrach H., Goborn J. Sample preparation protocols for MALDI-MS of peptides and oligonucleotides using prestructuredsample supports. Int Jornal of Mass Spectrom 2003; 226: 163-180.
10. Hutter-Paier В., Grygar E., Windisch M. Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivate Cerebrolysin. J Neural Transm, 1996, Suppl 47: 267-273.
11. Frey B., Andreazza A., Rosa A., Martins M., Valvassori S., Reus G., Hatch J., Quevedo J., Kapczinski F. Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behav Pharmacol 2006; 17: 4: 311-318.
12. Angelucci F., Aloe L., Jimenez-Vasquez P., Mathe A. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 2003; 6: 3: 225-231.
13. Hellweg R., Lang U., Nagel M., Baumgartner A. Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry 2002; 7: 6: 604-608.
14. Umbach J., Zhao Y., Gundersen C. Lithium enhances secretion from large dense-core vesicles in nerve growth factor-differentiated PC12 cells. J Neurochem 2005; 94: 5: 1306-1314.
15. Sivam S., Takeuchi K., Li S., Douglass J., Civelli O., Calvetta L., Herbert E., McGinty J., Hong J. Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats. Brain Res 1988; 427: 2: 155-163.
16. Staunton D., Deyo S., Shoemaker W., Ettenberg A., Bloom F. Effects of chronic lithium on enkephalin systems and pain responsiveness. Life Sci 1982; 31: 16-17: 1837-1840.
17. Byck R. Peptide transmitters: a unifying hypothesis for euphoria, respiration, sleep, and the action of lithium. Lancet 1976; 2: 7976: 72-73.
18. Plotnikov E., Grebenchikov O., Babenko V., Pevzner I., Zorova L., Likhvantsev V., Zorov D. Nephroprotective effect of GSK-3beta inhibition by lithium ions and delta-opioid receptor agonist dalargin on gentamicin-induced nephrotoxicity. Toxicol Lett 2013; 220: 3: 303-388.